SCHEMBL8185477

SCHEMBL8185477

CCc1ccc(C=C2SC(=O)NC2=S)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.74
PIM1 P11309 1/20 0.74
PIM2 Q9P1W9 1/20 0.74
RAB9A P51151 2/20 0.68
MEN1 O00255 2/20 0.68
ALDH1A1 P00352 2/20 0.68
LMNA P02545 2/20 0.68
MAPT P10636 2/20 0.68
HPGD P15428 2/20 0.68
KMT2A Q03164 2/20 0.68
POLB P06746 1/20 0.68
MAPK1 P28482 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
NPC1 O15118 1/20 0.67
MYC P01106 1/20 0.67
MAX P61244 1/20 0.67
TDP1 Q9NUW8 14/20 0.65
PNP P00491 1/20 0.65
CISD1 Q9NZ45 1/20 0.59
RECQL P46063 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8185473 1.00 IGF1R (0.74) IGF1RPIM1PIM2RAB9AMEN1
SCHEMBL8172752 0.86 MYC (0.73) IGF1RPIM1PIM2RAB9AMEN1
SCHEMBL8172749 0.86 MYC (0.73) IGF1RPIM1PIM2RAB9AMEN1
SCHEMBL2539569 0.85 PIM1 (1.00) IGF1RPIM1PIM2RAB9AHPGD
SCHEMBL2539573 0.85 PIM1 (1.00) IGF1RPIM1PIM2RAB9AHPGD
SCHEMBL2539566 0.85 PIM1 (1.00) IGF1RPIM1PIM2RAB9AHPGD
SCHEMBL8172523 0.83 HPGD (0.59) IGF1RPIM1PIM2RAB9AMEN1
SCHEMBL8172525 0.83 HPGD (0.59) IGF1RPIM1PIM2RAB9AMEN1
SCHEMBL8186903 0.82 TDP1 (0.61) PIM1PIM2RAB9AMEN1ALDH1A1
SCHEMBL8186906 0.82 TDP1 (0.61) PIM1PIM2RAB9AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000018746-A1 THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed